Since the last renewal, the previous Tissue Procurement Facility and Research Histology Shared Resource have merged and expanded their functions to form the Biorepository and Tissue Research Facility (BTRF), under new leadership. The BTRF makes human biospecimens available for basic, translational, and clinical research. It is the major conduit through which human tissue specimens are transferred from the Pathology, Surgery and other clinical departments to research labs at the University of Virginia (UVA), and is the major processor of human biospecimens (tissue, blood, urine) in support of clinical trials at UVA. In addition, this is the only shared research facility that supports standard histology services and complex histology-based analytic techniques for animal models and human tissues, including tissue microarray construction, laser microdissection, immunohistochemistry, digital slide scanning and reverse-phase protein microarrays. Expert histopathology support from Board-certified Anatomic Pathologists is provided for these activities through this Shared Resource. The biorepository and analytic services are often vertically integrated with each other to allow for one-stop shopping for investigators carrying out translational or clinical cancer research. BTRF services make possible new insights into cancer disease mechanisms by the analysis of tissues and biofluids, assist in the discovery and validation of new clinical cancer biomarkers, and support clinical trials of novel diagnostic tests and therapies for cancer.

Public Health Relevance

Analysis of human tissues is the conduit through which new knowledge about molecules and cells enters the realm of clinical practice. The BTRF provides both tissues and analytic tools to advance cancer diagnosis, prognosis, and treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-24
Application #
8823561
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2016-01-31
Budget Start
2015-02-01
Budget End
2016-01-31
Support Year
24
Fiscal Year
2015
Total Cost
$107,099
Indirect Cost
$48,220
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Manukyan, Arkadi; Kowalczyk, Izabela; Melhuish, Tiffany A et al. (2018) Analysis of transcriptional activity by the Myt1 and Myt1l transcription factors. J Cell Biochem 119:4644-4655
Engelhard, Victor H; Rodriguez, Anthony B; Mauldin, Ileana S et al. (2018) Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. J Immunol 200:432-442
Martins, André L; Walavalkar, Ninad M; Anderson, Warren D et al. (2018) Universal correction of enzymatic sequence bias reveals molecular signatures of protein/DNA interactions. Nucleic Acids Res 46:e9
Michaels, Alex D; Newhook, Timothy E; Adair, Sara J et al. (2018) CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clin Cancer Res 24:1415-1425
Shi, Lei; Li, Kang; Guo, Yizhan et al. (2018) Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc Natl Acad Sci U S A 115:11808-11813
Yang, Jun; LeBlanc, Francis R; Dighe, Shubha A et al. (2018) TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia. Blood 131:2803-2815
Kulling, Paige M; Olson, Kristine C; Hamele, Cait E et al. (2018) Dysregulation of the IFN-?-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. PLoS One 13:e0193429
Grant, Margaret J; Loftus, Matthew S; Stoja, Aiola P et al. (2018) Superresolution microscopy reveals structural mechanisms driving the nanoarchitecture of a viral chromatin tether. Proc Natl Acad Sci U S A 115:4992-4997
Knapp, Kiley A; Pires, Eusebio S; Adair, Sara J et al. (2018) Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Oncotarget 9:8972-8984
Zhang, Xuewei; Kitatani, Kazuyuki; Toyoshima, Masafumi et al. (2018) Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer. Mol Cancer Ther 17:50-59

Showing the most recent 10 out of 539 publications